and the future of oncology.
作者信息
Zielinski Christoph C
机构信息
Department of Medicine I, Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
出版信息
ESMO Open. 2016 Jan 18;1(1):e000008. doi: 10.1136/esmoopen-2015-000008. eCollection 2016.
Abstract
摘要
相似文献
1
and the future of oncology.
ESMO Open. 2016 Jan 18;1(1):e000008. doi: 10.1136/esmoopen-2015-000008. eCollection 2016.
2
Introducing pro and con discussions in ESMO Open-Cancer Horizons.
ESMO Open. 2022 Jun;7(3):100467. doi: 10.1016/j.esmoop.2022.100467. Epub 2022 Apr 19.
3
ESMO Open: from Cancer Horizons to Science for Optimal Cancer Care-a tale stretching over 8 years.
ESMO Open. 2023 Dec;8(6):102072. doi: 10.1016/j.esmoop.2023.102072. Epub 2023 Dec 15.
4
AIOM chooses as its official journal: a warm welcome from .
ESMO Open. 2016 Jul 1;1(4):e000080. doi: 10.1136/esmoopen-2016-000080. eCollection 2016.
5
One year of : -where are we going from here?
ESMO Open. 2017 Jan 23;1(6):e000153. doi: 10.1136/esmoopen-2016-000153. eCollection 2016.
6
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).
ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016.
7
CSCO joins ESMO Open-Cancer Horizons.
ESMO Open. 2016 Nov 18;1(5):e000120. doi: 10.1136/esmoopen-2016-000120. eCollection 2016.
8
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.
ESMO Open. 2019 Jun 12;4(Suppl 3):e000501. doi: 10.1136/esmoopen-2019-000501. eCollection 2019.
9
Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
Lung Cancer. 2014 Jul;85(1):74-80. doi: 10.1016/j.lungcan.2014.03.010. Epub 2014 Mar 16.
10
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an pro and con discussion.
ESMO Open. 2019 Nov 13;4(6):e000565. doi: 10.1136/esmoopen-2019-000565. eCollection 2019.
引用本文的文献
1
Awareness of predatory journals and open access among medical oncologists: results of an online survey.
ESMO Open. 2019 Nov 27;4(6):e000580. doi: 10.1136/esmoopen-2019-000580. eCollection 2019.
本文引用的文献
1
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.
J Clin Oncol. 2015 Aug 10;33(23):2563-77. doi: 10.1200/JCO.2015.61.6706. Epub 2015 Jun 22.
2
Proven efficacy, equitable access, and adjusted pricing of anti-cancer therapies: no 'sweetheart' solution.
Ann Oncol. 2015 Aug;26(8):1529-31. doi: 10.1093/annonc/mdv258. Epub 2015 Jun 4.
3
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30.
4
Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.
J Clin Oncol. 2013 May 20;31(15):1858-65. doi: 10.1200/JCO.2012.45.9867. Epub 2013 Apr 15.
5
Delivering affordable cancer care in high-income countries.
Lancet Oncol. 2011 Sep;12(10):933-80. doi: 10.1016/S1470-2045(11)70141-3.
6
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
Zotero 插件